For Advanced HIV, 2-Drug Dovato Regimen as Effective as 3 Drugs

The two-drug regimen of dolutegravir-lamivudine achieves comparable efficacy to three-drug therapy regimens in ...

FEBRUARY 28, 2025

Overcoming the Challenges of Adhering to Injectable ART and PrEP

Before 2021, oral medication was the only option for HIV prevention and treatment, but adherence has always been a ...

JUNE 26, 2024

Injectable PrEP Highly Effective, But Oral Bridging May Be Useful After Missed Appointments

People given injectable long-acting cabotegravir as pre-exposure prophylaxis for HIV have higher levels of ...

JUNE 20, 2024

FDA Grants New Indication for Dovato to Treat Adolescents 12 and Older

The FDA granted a new indication for Dovato to treat HIV-1 infection in adolescents 12 years of age and older and ...

APRIL 8, 2024

New Fellowship to Improve HIV Prevention in Key Communities Available

A new fellowship—The Dr. Dawn K. Smith HIV Prevention Clinical Fellowship—to provide comprehensive HIV ...

MARCH 5, 2024

New Blister Packs Available for Dovato

ViiV Healthcare announced that dolutegravir-lamivudine (DTG/3TC; Dovato) is now available in a blister pack in the ...

FEBRUARY 5, 2024

CAB+RPV Long-Acting Injections Effective as ART

Cabenuva long-acting injections are effective at controlling HIV, with 96% of users maintaining a viral load of ...

DECEMBER 21, 2023

Cisgender Women in 7 African Countries Prefer Long-Acting Cabotegravir PrEP

Nearly eight out of 10 cisgender women preferred long-acting injectable cabotegravir to daily oral pre-exposure ...

JULY 26, 2023

Fostemsavir Data Looking Bright for Heavily Treatment-Experienced Adults With MDR HIV

After 240 weeks, fostemsavir helped HTE adults with MDR HIV-1 infection achieve durable virologic responses, ...

AUGUST 3, 2022

FDA Grants New Indication for Cabenuva for Every-8–Week Dosing

The FDA extended the time between shots of Cabenuva to every two months to treat HIV-1 infection in virologically ...

FEBRUARY 1, 2022

FDA Approves Cabenuva Long-Acting HIV Treatment

cabotegravir plus rilpivirine is dosed once monthly as an option to replace a patient’s current ...

JANUARY 22, 2021

ViiV Enters Exclusive Licensing Agreement With NIH for Long-Term HIV Treatment

Broadly neutralizing antibodies can recognize and block the entry of different strains of HIV into healthy cells.

DECEMBER 2, 2019